Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial
ConclusionsThese results highlight the clinical, biological, and metabolic heterogeneity of HER2+ breast cancer, which may facilitate the selection of HER2+ EBC patients likely to benefit from [18F]FDG-PET imaging as a tool to guide therapy.Trial registrationClinicaltrials.gov; NCT03161353; registration date: May 15, 2017.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Genetics | HER2 | Herceptin | Hormones | Molecular Biology | MRI Scan | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Nuclear Medicine | PET Scan | Study